Table 4

Change in medication use in 12 months prior to versus postinitiation of mepolizumab

MedicationPremepolizumab mean-weighted average dispensingsPre-SDPostmepolizumab mean-weighted average dispensingsPost-SDPer cent reduction (negative indicates increase)
Single controller medication
 Low ICS or medium-dose ICS0.7430.713.35
 High-dose ICS0.612.80.673.4−10
 Oral corticosteroids (28+ days)−5
 ICS/LABA (any dose)−4
 Low-dose ICS/LABA1.83.123.7−9
 Medium-dose or high-dose ICS/ LABA0.913.30.863.85
 Low-dose or medium-dose ICS/ LTRA0.342.20.332.63
 High-dose ICS/ LTRA0.292.10.312.6−7
 Oral corticosteroids (3–27 days)
  • Paired measurements were not available due to aggregated nature of data.

  • ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonists; SABA, short-acting beta agonist.